AMD patients undermonitored, undertreated in real-world scenarios, observational study shows

COPENHAGEN, Denmark — An observational study conducted at several locations in Europe, Australia, Canada and Venezuela showed that, in a real-world scenario, treatment with ranibizumab for wet age-related macular degeneration had poorer-than-expected visual outcomes due to irregular monitoring and a low number of treatments per year. "In clinical practice, as-needed or treat-and-extend dosing regimens are generally adopted, but on the whole they don’t seem to produce good results," Sobha Sivaprasad, MD, at the meeting of the European Society of Ophthalmology.

Full Story →